ACE and diabetic kidney disease: Blockage of RAAS utilizing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has been found to reduce proteinuria, thus slowing diabetic kidney disease progression and reducing cardiovascular mortality and morbidity [6].